Cresset gains access to ADME models, and Optibrium gets access to FieldAlign SAR software.

U.K.-based Cresset and Optibrium inked a collaboration through which each firm will provide the other with access to specific in silico drug discovery solutions. Under terms of the technology exchange agreement, users of Cresset’s desktop applications will have access to Optibrium’s ADME models solution, which is currently provided as a plug-in module for its StarDrop software platform. Cresset’s FieldAlign SAR software will in return be made available as an optional plug-in module to StarDrop. Optibrium claims use of the FieldAlign module will provide a 3-D view of compound interactions to complement the software’s existing 2-D QSAR models.

Optibrium was established in 2009 as a spin-out from BioFocus DPI, to develop and commercialize the StarDrop software suite for use in drug candidate design, selection, and decision making. StarDrop integrates in silico and experimentally measured properties using a multiparameter optimization approach, chemical space, and Glowing Molecule™ visualizations and predictive modeling.

Cresset’s Field technology is being exploited to provide insights into the biological activity, properties, and interactions of drug molecules. The firm has developed a range of solutions based on the platform, for applications in ligand-based virtual screening (FIeldScreen), bioisostere identification (FieldStere), bioactive conformation determination (FieldTemplater), as well as ligand alignment (FieldAlign). 

Previous articleChimps Get a Break
Next articleProbiodrug Secures €15M to Progress Glutaminyl Cyclase Inhibitor Alzheimer Drug